Sarcomatoid urothelial carcinoma: advances and challenges

The implications of new developments in clinical practice range from the corrected differential diagnosis of sarcomatoid urothelial carcinoma from its mimics to the potential value of neoadjuvant chemotherapy followed by radical cystectomy, and the use of immune checkpoint inhibitors in metastatic sarcomatoid urothelial cancer, which improve clinical management and offer survival benefits for these patients. The use of novel therapies targeting molecular pathways represents a significant advance, enabling more precise and individualized treatment strategies.